Cargando…
A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer
BACKGROUND: Gastric cancer presents a major health burden worldwide. Therefore, many molecular targeting agents have been evaluated for treatment of gastric cancer. Gefitinib has shown anticancer activity against gastric cancer which work through inhibiting epidermal growth factor receptor (EGFR). H...
Autores principales: | Huafeng, Jia, Deqing, Zhang, Yong, Ding, Yulian, Zhang, Ailing, Hu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879569/ https://www.ncbi.nlm.nih.gov/pubmed/29618949 http://dx.doi.org/10.1186/s12935-018-0548-5 |
Ejemplares similares
-
Epidermal growth factor-mediated Rab25 pathway regulates integrin β1 trafficking in colon cancer
por: Hong, Kyung Sook, et al.
Publicado: (2018) -
Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
por: Ju, Lixia, et al.
Publicado: (2013) -
Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
por: Sun, Heng, et al.
Publicado: (2018) -
Silencing Formin-like 2 inhibits growth and metastasis of gastric cancer cells through suppressing internalization of integrins
por: Zhong, Banghua, et al.
Publicado: (2018) -
Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells
por: Watt, Heather L, et al.
Publicado: (2006)